Kajian potensi interaksi obat pada peresepan diabetes melitus
DOI:
https://doi.org/10.32504/hspj.v8i1.940Keywords:
Drug Interactions, Diabetes Mellitus, PrescriptionsAbstract
Diabetes melitus (DM) merupakan penyakit degeneratif dengan prevalensi yang terus meningkat. Komplikasi dan komorbid yang = banyak muncul pada penderita DM menyebabkan pengobatan dengan polifarmasi tidak dapat dihindari. Adanya polifarmasi akan meningkatkan potensi interaksi obat (IO) yang kemungkinan dapat meningkatkan reaksi obat merugikan. Penelitian ini bertujuan untuk menganalisis potensi kejadian IO pada peresepan DM di salah satu apotek di Kota Surabaya, Jawa Timur. Potensi IO dari 116 lembar resep dianalisis menggunakan online interaction checker drugs.com. Prevalensi, keparahan, mekanisme, serta manifestasi potensi IO dianalisis secara deskriptif. Dari jumlah lembar resep tersebut potensi IO ditemukan pada 67 lembar resep (57,7%) sebanyak 124 potensi kejadian. Mayoritas potensi IO adalah interaksi farmakodinamik (93,6%) dan memiliki keparahan moderat (87,1%). Kombinasi obat berpotensi IO yang paling banyak diresepkan adalah metformin dan glimepiride yaitu sebanyak 32,3% yang memiliki manifestasi peningkatan hipoglikemi. Pengontrolan kadar gula darah pasien DM secara rutin sangat diperlukan untuk mencegah timbulnya resiko yang tidak diinginkan karena hipoglikemia. Selain itu, dalam pelayanan resep diabetes hendaknya informasi tentang monitoring kadar gula darah dan gejala hipoglikemia disampaikan kepada pasien terkait tingginya potensi IO dengan manifestasi peningkatan resiko hipoglikemia.
Kata kunci: Diabetes melitus; interaksi obat; peresepan.
References
Goyal R, Ishwarlal J. Diabetes Mellitus Type 2. Treasure Island (FL): StatPearls Publishing; 2022.
World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications Report of a WHO Consltation. Geneva: WHO Department of Noncommunicable Disease Surveillance; 2011.
Kementerian Kesehatan RI. Riset Kesehatan Dasar. Jakarta: Departemen Kesehatan RI; 2018.
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017 Dec;17(1):230.
Kennedy C, Brewer L, Williams D. Drug interactions. Medicine (Baltimore). 2020 Jul;48(7):450–5.
Shin H, Schneeweiss S, Glynn RJ, Patorno E. Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA. Diabetes Care. 2021 Aug 1;44(8):1774–82.
Baker C, Retzik-Stahr C, Singh V, Plomondon R, Anderson V, Rasouli N. Should metformin remain the first-line therapy for treatment of type 2 diabetes? Ther Adv Endocrinol Metab. 2021 Jan;12:204201882098022.
Amod A. The Place of Sulfonylureas in Guidelines: Why Are There Differences? Diabetes Ther Res Treat Educ Diabetes Relat Disord. 2020 Jun;11(Suppl 1):5–14.
Long AN, Dagogo-Jack S. Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection. J Clin Hypertens. 2011 Apr;13(4):244–51.
Drugsite Trust. Drug Interaction Classification [Internet]. Drugsite Trust; 2023 [cited 2023 Jan 6]. Available from: https://www.drugs.com/drug_interactions.html
Nakhleh A, Shehadeh N. Hypoglycemia in diabetes: An update on pathophysiology, treatment, and prevention. World J Diabetes. 2021 Dec 15;12(12):2036–49.
Paluchamy T. Hypoglycemia: Essential Clinical Guidelines. In: Szablewski L, editor. Blood Glucose Levels [Internet]. IntechOpen; 2020 [cited 2023 Jan 6]. Available from: https://www.intechopen.com/books/blood-glucose-levels/hypoglycemia-essential-clinical-guidelines
Drugsite Trust. Drug Interactions Report : Bisoprolol + Glimepiride [Internet]. Drugsite Trust; 2023 [cited 2023 Jan 6]. Available from: https://www.drugs.com/drug_interactions.html
Downloads
Published
Issue
Section
Citation Check
License
Copyright (c) 2024 Ilil Maidatuz Zulfa, Rizky Kurnia Rumangkang
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Formal legal provisions for accessing digital articles in electronic journals must be based on the Creative Commons Attribution-ShareAlike (CC BY-SA) license terms, which means the Health Sciences and Pharmacy Journal reserves to save, to transfer media / format, to manage in the form of databases, to maintain, and to publish articles without asking permission from the author as long as they include the author's name as the copyright owner.
